Skip to Main Content

Biogen is declaring success with a once-failed treatment for Alzheimer’s disease, pointing to positive secondary results from a mid-stage study in hopes of saving a drug many in the field had written off entirely.

The treatment, BAN2401, failed its primary goal of beating out placebo over the course of 12 months. But looking at 18 months worth of data from the Phase 2 trial, Biogen and its partner, Japanese drug maker Eisai, said late Thursday that one dose of the treatment — the highest of five tested — had a significant effect on both cognition and the accumulation of toxic plaques in the brain.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Hi,
    Please tell me how I could be part of the BAN 2401 Study or receive this medication. I have early Alzheimers & take care of my special needs daughter. I am an otherwise healthy 76 year old man who makes people laugh. Thank you very much, Anthony Robbins

  • Terrific work Biogen. Great news that this result showed slowing of decreased cognitive ability.
    The next step is to get the drug to correlate to increased cognitive ability. It will happen!

  • Anavex Life Science (AVXL) drug has a totally different mechanism than these other failed drugs and has shown very promising phase 2 data. Phase 2b/3 trial starting within the next month or two.

Comments are closed.